Adrienne Other Cancer |  Diagnosed 2013

"Cancer research not only saved my life but will potentially save members of my family."

Adrienne's Story

In 2005, Adrienne learned she had Lynch syndrome, an inherited genetic mutation that significantly increased her risk for several types of cancer. Eight years later, she was diagnosed with metastatic ampullary cancer. She underwent 13 months of chemotherapy, which did not work. When genetic testing of Adrienne’s tumor showed it was microsatellite instability-high (MSI-H), her oncologist recommended she enroll in a clinical trial for pembrolizumab (Keytruda®). Just over two months later, the cancer was gone. She continued to receive treatment for two years, traveling from her home in New York to Johns Hopkins in Baltimore. Over two years since her last treatment, she remains cancer-free and has returned to her busy life working, spending time with her four daughters, practicing yoga, playing tennis, and traveling with friends and family.

UPDATE, December 2019: Adrienne remains cancer-free and spoke at the CRI Immunotherapy Patient Summit in Baltimore on November 16, 2019.

I imagine a future where genetic markers enable us to both detect risk and prevent cancer. - Adrienne, Immunotherapy Patient

We're Stronger Together

Provide guidance and encouragement to others going through their journey with cancer immunotherapy treatment.

Share Your Story
Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.

Patient education information supported by a charitable donation from Bristol-Myers Squibb Company.